Major financial institutions are executing significant portfolio adjustments involving Altria Group, creating a fascinating divergence in market sentiment. Recent regulatory filings reveal that while some advisory firms are substantially increasing their holdings, others are dramatically reducing their exposure to the tobacco giant.
Conflicting Investment Moves Emerge
According to mandatory disclosures filed on November 17, Avantax Advisory Services boosted its position by 6.4 percent, while Slagle Financial expanded its stake by an even more substantial 7.1 percent. These bullish moves contrast sharply with decisions from other institutional players. Cornerstone Advisors executed a dramatic reduction, slashing its holdings by 67.2 percent through the sale of 28,300 shares. Meanwhile, Banco Bilbao Vizcaya Argentaria trimmed its position by 13.6 percent.
These opposing investment strategies followed shortly after Altria’s late October earnings release. The company had reported adjusted earnings of $1.45 per share, slightly exceeding analyst projections. However, revenue figures disappointed market observers, coming in at $5.25 billion against expectations of $5.31 billion and representing a 3 percent year-over-year decline.
Should investors sell immediately? Or is it worth buying Altria?
Traditional Business Challenges Versus New Opportunities
The company’s core cigarette business continues to face volume declines, prompting Altria to implement aggressive pricing strategies while expanding its smoke-free product portfolio. The corporation’s nicotine pouch brand, on!, demonstrates particularly strong growth momentum. In a notable development, Altria plans to launch its next-generation product, on! PLUS, this autumn despite awaiting formal FDA marketing authorization—a calculated risk in an increasingly restrictive regulatory environment.
Management has refined its full-year 2025 guidance to a range between $5.37 and $5.45 per share, representing projected growth of 3.5 to 5 percent. Simultaneously, the board has authorized a share repurchase program expansion to $2 billion, signaling confidence in the company’s financial stability and future prospects.
Market analysts maintain a cautious stance overall, with most recommending a “hold” position on the stock. The attractive dividend yield of approximately 7.3 percent continues to draw income-focused investors, though this must be weighed against persistent volume challenges and ongoing regulatory uncertainties facing the tobacco industry.
Ad
Altria Stock: Buy or Sell?! New Altria Analysis from November 17 delivers the answer:
The latest Altria figures speak for themselves: Urgent action needed for Altria investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 17.
Altria: Buy or sell? Read more here...
